Table 1 Group (nine mice each group) summary for in vivo efficacy study.

Gp	Treatment	Dose (mg/kg)	Dose schedule	Max % weight change	% Treatment-related deaths	Efficacy			Survival
Gp	Treatment	Dose (mg/kg)	Dose schedule	Max % weight change	% Treatment-related deaths	Tumor growth delay (days)	Median % ΔT/C (day 36)	%CR^e	%TFS^f	Median lifespan (days)^c	% Increased lifespan
1	Vehicle	0.2 ml/20 g	5QW^a	–13.6	--	--	--	--	--	30	--
2	VIS832	4.0	2QW	–4.3^d	0.0	13.9	1.1	22.2		>60	>100
3	btz	1.0^b	2QW	–13.6	11.1	10.6	8.2	0		42	40
4	VIS832+	1.0^b	2QW	–9.8	0.0	>45	0.0	100	>90	>60	>100
	btz	4.0

^aVehicle (PBS) administered by oral gavage.
^bDose level of bortezomib adjusted down from 2 mg/kg (2QW) to 1 mg/kg on day 18 due to toxicity including the death of one animal in treatment group (Gp).
^cMeasured from the day of first treatment in the study (not the day of tumor implant) for each animal. It captures the day of death for all animals that either die or are euthanized for disease or treatment-related causes. Animals euthanized for sampling or other reasons unrelated to disease or therapy (e.g., end of study) are excluded from this calculation.
^dNegative change in weight observed during initial dosing only (see Fig. 6d).
^eComplete regression (CR) (see Supplementary Tables S3 and 4).
^fTumor-free survivor (TFS) (see Supplementary Tables S3 and 4).

Quick links

Search